Association Between Beta-Blockers and Mortality and Readmission in Older Patients with Heart Failure: an Instrumental Variable Analysis.
beta-blockers
cardiology
geriatrics
heart failure
instrumental variable analysis
Journal
Journal of general internal medicine
ISSN: 1525-1497
Titre abrégé: J Gen Intern Med
Pays: United States
ID NLM: 8605834
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
15
07
2020
accepted:
30
04
2021
pubmed:
9
6
2021
medline:
8
9
2021
entrez:
8
6
2021
Statut:
ppublish
Résumé
The demographics of heart failure are changing. The rate of growth of the "older" heart failure population, specifically those ≥ 75, has outpaced that of any other age group. These older patients were underrepresented in the early beta-blocker trials. There are several reasons, including a decreased potential for mortality benefit and increased risk of side effects, why the risk/benefit tradeoff may be different in this population. We aimed to determine the association between receipt of a beta-blocker after heart failure discharge and early mortality and readmission rates among patients with heart failure and reduced ejection fraction (HFrEF), specifically patients aged 75+. We used 100% Medicare Parts A and B and a random 40% sample of Part D to create a cohort of beneficiaries with ≥ 1 hospitalization for HFrEF between 2008 and 2016 to run an instrumental variable analysis. The primary measure was 90-day, all-cause mortality; the secondary measure was 90-day, all-cause readmission. Using the two-stage least squared methodology, among all HFrEF patients, receipt of a beta-blocker within 30-day of discharge was associated with a - 4.35% (95% CI - 6.27 to - 2.42%, p < 0.001) decrease in 90-day mortality and a - 4.66% (95% CI - 7.40 to - 1.91%, p = 0.001) decrease in 90-day readmission rates. Even among patients ≥ 75 years old, receipt of a beta-blocker at discharge was also associated with a significant decrease in 90-day mortality, - 4.78% (95% CI - 7.19 to - 2.40%, p < 0.001) and 90-day readmissions, - 4.67% (95% CI - 7.89 to - 1.45%, p < 0.001). Patients aged ≥ 75 years who receive a beta-blocker after HFrEF hospitalization have significantly lower 90-day mortality and readmission rates. The magnitude of benefit does not appear to wane with age. Absent a strong contraindication, all patients with HFrEF should attempt beta-blocker therapy at/after hospital discharge, regardless of age.
Sections du résumé
BACKGROUND
The demographics of heart failure are changing. The rate of growth of the "older" heart failure population, specifically those ≥ 75, has outpaced that of any other age group. These older patients were underrepresented in the early beta-blocker trials. There are several reasons, including a decreased potential for mortality benefit and increased risk of side effects, why the risk/benefit tradeoff may be different in this population.
OBJECTIVE
We aimed to determine the association between receipt of a beta-blocker after heart failure discharge and early mortality and readmission rates among patients with heart failure and reduced ejection fraction (HFrEF), specifically patients aged 75+.
DESIGN AND PARTICIPANTS
We used 100% Medicare Parts A and B and a random 40% sample of Part D to create a cohort of beneficiaries with ≥ 1 hospitalization for HFrEF between 2008 and 2016 to run an instrumental variable analysis.
MAIN MEASURE
The primary measure was 90-day, all-cause mortality; the secondary measure was 90-day, all-cause readmission.
KEY RESULTS
Using the two-stage least squared methodology, among all HFrEF patients, receipt of a beta-blocker within 30-day of discharge was associated with a - 4.35% (95% CI - 6.27 to - 2.42%, p < 0.001) decrease in 90-day mortality and a - 4.66% (95% CI - 7.40 to - 1.91%, p = 0.001) decrease in 90-day readmission rates. Even among patients ≥ 75 years old, receipt of a beta-blocker at discharge was also associated with a significant decrease in 90-day mortality, - 4.78% (95% CI - 7.19 to - 2.40%, p < 0.001) and 90-day readmissions, - 4.67% (95% CI - 7.89 to - 1.45%, p < 0.001).
CONCLUSION
Patients aged ≥ 75 years who receive a beta-blocker after HFrEF hospitalization have significantly lower 90-day mortality and readmission rates. The magnitude of benefit does not appear to wane with age. Absent a strong contraindication, all patients with HFrEF should attempt beta-blocker therapy at/after hospital discharge, regardless of age.
Identifiants
pubmed: 34100232
doi: 10.1007/s11606-021-06901-7
pii: 10.1007/s11606-021-06901-7
pmc: PMC8342662
doi:
Substances chimiques
Adrenergic beta-Antagonists
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2361-2369Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR001086
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL142835
Pays : United States
Organisme : NIA NIH HHS
ID : P01 AG019783
Pays : United States
Informations de copyright
© 2021. Society of General Internal Medicine.
Références
Ward C, Ewald E, Koenig K, et al. Prevalence and Health Care Expenditures among Medicare Beneficiaries Aged 65 Years and Over with Heart Conditions. 2017.
Saczynski JS, Go AS, Magid DJ, et al. Patterns of comorbidity in older adults with heart failure: the Cardiovascular Research Network PRESERVE study. Journal of the American Geriatrics Society. 2013;61(1):26-33.
doi: 10.1111/jgs.12062
Jackson SL, Tong X, King RJ, et al. National Burden of Heart Failure Events in the United States, 2006 to 2014. Circ Heart Fail. 2018;11(12):e004873.
doi: 10.1161/CIRCHEARTFAILURE.117.004873
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (London, England). 1999;353(9146):9-13.
Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (London, England). 1999;353(9169):2001-7.
doi: 10.1016/S0140-6736(99)04440-2
Beta-Blocker Evaluation of Survival Trial I, Eichhorn EJ, Domanski MJ, et al. A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. The New England journal of medicine. 2001;344(22):1659-67.
doi: 10.1056/NEJM200105313442202
Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. The New England journal of medicine. 2001;344(22):1651-8.
doi: 10.1056/NEJM200105313442201
Flather MD, Shibata MC, Coats AJ, et al. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). European heart journal. 2005;26(3):215-25.
doi: 10.1093/eurheartj/ehi115
Gilstrap LG, Austin AM, Gladders B, et al. Beta Blockers After HFrEF Hospitalization Decrease Short Term Mortality Across the Age Spectrum. Circulation. 2019. https://www.ahajournals.org/doi/10.1161/circ.140.suppl_1.14844 .
Gilstrap LG, Austin AM, Gladders B, et al. Beta Blockers After HFrEF Hospitalization Decrease 1-Year Mortality Across the Age Spectrum Circulation. 2019;140. https://www.ahajournals.org/doi/10.1161/circ.140.suppl_1.14853 .
Sukul D, Hoffman GJ, Nuliyalu U, et al. Association Between Medicare Policy Reforms and Changes in Hospitalized Medicare Beneficiaries' Severity of Illness. JAMA Netw Open. 2019;2(5):e193290.
doi: 10.1001/jamanetworkopen.2019.3290
Yeh RW, Vasaiwala S, Forman DE, et al. Instrumental variable analysis to compare effectiveness of stents in the extremely elderly. Circ Cardiovasc Qual Outcomes. 2014;7(1):118-24.
doi: 10.1161/CIRCOUTCOMES.113.000476
Kramer DB, Normand ST, Volya R, et al. Facility-Level Variation and Clinical Outcomes in Use of Cardiac Resynchronization Therapy With and Without an Implantable Cardioverter-Defibrillator. Circ Cardiovasc Qual Outcomes. 2018;11(12):e004763.
doi: 10.1161/CIRCOUTCOMES.118.004763
Li Q, Glynn RJ, Dreyer NA, et al. Validity of claims-based definitions of left ventricular systolic dysfunction in Medicare patients. Pharmacoepidemiol Drug Saf. 2011;20(7):700-8.
doi: 10.1002/pds.2146
Loop MS, Van Dyke MK, Chen L, et al. Comparison of Length of Stay, 30-Day Mortality, and 30-Day Readmission Rates in Medicare Patients With Heart Failure and With Reduced Versus Preserved Ejection Fraction. Am J Cardiol. 2016;118(1):79-85.
doi: 10.1016/j.amjcard.2016.04.015
Medicare Hospital Quality Chartbook, 2010 - Performance Report on Outcomes Measures for Acute Myocardial Infarction, Heart Failure, and Pneumonia. 2010.
Dudl RJ, Wang MC, Wong M, et al. Preventing myocardial infarction and stroke with a simplified bundle of cardioprotective medications. Am J Manag Care. 2009;15(10):e88-94.
pubmed: 19817511
Ramirez SP, Albert JM, Blayney MJ, et al. Rosiglitazone is associated with mortality in chronic hemodialysis patients. J Am Soc Nephrol. 2009;20(5):1094-101.
doi: 10.1681/ASN.2008060579
Tentori F, Albert JM, Young EW, et al. The survival advantage for haemodialysis patients taking vitamin D is questioned: findings from the Dialysis Outcomes and Practice Patterns Study. Nephrol Dial Transplant. 2009;24(3):963-72.
doi: 10.1093/ndt/gfn592
Salkever D, Slade E, Karakus M. Differential effects of atypical versus typical antipsychotic medication on earnings of schizophrenia patients : estimates from a prospective naturalistic study. Pharmacoeconomics. 2006;24(2):123-39.
doi: 10.2165/00019053-200624020-00003
Salkever DS, Slade EP, Karakus M, et al. Estimation of antipsychotic effects on hospitalization risk in a naturalistic study with selection on unobservables. J Nerv Ment Dis. 2004;192(2):119-28.
doi: 10.1097/01.nmd.0000110283.89270.23
Martinez-Camblor P, Mackenzie T, Staiger DO, et al. Adjusting for bias introduced by instrumental variable estimation in the Cox proportional hazards model. Biostatistics. 2019;20(1):80-96.
doi: 10.1093/biostatistics/kxx062
Stukel TA, Fisher ES, Wennberg DE, et al. Analysis of observational studies in the presence of treatment selection bias: effects of invasive cardiac management on AMI survival using propensity score and instrumental variable methods. JAMA. 2007;297(3):278-85.
doi: 10.1001/jama.297.3.278
Malenka DJ, Kaplan AV, Lucas FL, et al. Outcomes following coronary stenting in the era of bare-metal vs the era of drug-eluting stents. JAMA. 2008;299(24):2868-76.
doi: 10.1001/jama.299.24.2868
Brookhart MA, Wang PS, Solomon DH, et al. Evaluating short-term drug effects using a physician-specific prescribing preference as an instrumental variable. Epidemiology. 2006;17(3):268-75.
doi: 10.1097/01.ede.0000193606.58671.c5
Chen Y, Briesacher BA. Use of instrumental variable in prescription drug research with observational data: a systematic review. J Clin Epidemiol. 2011;64(6):687-700.
doi: 10.1016/j.jclinepi.2010.09.006
Rassen JA, Brookhart MA, Glynn RJ, et al. Instrumental variables I: instrumental variables exploit natural variation in nonexperimental data to estimate causal relationships. J Clin Epidemiol. 2009;62(12):1226-32.
doi: 10.1016/j.jclinepi.2008.12.005
Bosco JL, Silliman RA, Thwin SS, et al. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol. 2010;63(1):64-74.
doi: 10.1016/j.jclinepi.2009.03.001
Staiger D, Stock D. Instrumental Variable Regression with Weak Instruments. Econometric. 1007;65(3):557-86.
Lu-Yao GL, Albertsen PC, Moore DF, et al. Survival following primary androgen deprivation therapy among men with localized prostate cancer. JAMA. 2008;300(2):173-81.
doi: 10.1001/jama.300.2.173
Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ. 2007;176(5):627-32.
doi: 10.1503/cmaj.061250
Angrist JD. Estimation of Limited Dependent Variable Models With Dummy Endogenous Regressors: Simple Strategies for Empirical Practice. Journal of Business and Economic Statistics. 2001;19:2-28.
doi: 10.1198/07350010152472571
Writing Committee M, Yancy CW, Jessup M, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128(16):e240-327.
Masoudi FA, Havranek EP, Wolfe P, et al. Most hospitalized older persons do not meet the enrollment criteria for clinical trials in heart failure. Am Heart J. 2003;146(2):250-7.
doi: 10.1016/S0002-8703(03)00189-3
Azad N, Lemay G. Management of chronic heart failure in the older population. J Geriatr Cardiol. 2014;11(4):329-37.
pubmed: 25593582
pmcid: 4292097
Chronic Conditions Among Medicare Beneficiaries. 2012. https://www2.ccwdata.org/web/guest/condition‐categories .
Liu LF. The health heterogeneity of and health care utilization by the elderly in Taiwan. Int J Environ Res Public Health. 2014;11(2):1384-97.
doi: 10.3390/ijerph110201384
Dungen HD, Apostolovic S, Inkrot S, et al. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail. 2011;13(6):670-80.
doi: 10.1093/eurjhf/hfr020
Gilstrap LG, Chernew ME, Nguyen CA, et al. Association Between Clinical Practice Group Adherence to Quality Measures and Adverse Outcomes Among Adult Patients With Diabetes. JAMA Netw Open. 2019;2(8):e199139.
doi: 10.1001/jamanetworkopen.2019.9139